does cbd shrink tumors

December 15, 2021 By admin Off

In this meeting, she revealed that she had been taking CBD oil “as an alternative self-treatment for her lung cancer” since August 2018, which she had sourced from outside of the U.K. She was taking 0.5 ml of the CBD oil, two-three times per day.

TORONTO — A case study of a U.K. woman whose lung tumour shrunk without the aid of conventional treatments while she was taking a daily dose of cannabidiol (CBD) oil has scientists suggesting it may be worth studying the use of CBD oil further.

She had noticed a reduced appetite since taking the CBD oil, but apart from that, she had no other changes to her prescribed medications, diet or lifestyle — she was even still smoking one pack of cigarettes a week still, despite being advised to quit.

In 2019, the shrinking of the tumour piqued doctors’ interests, and the patient was brought in to discuss her results.

The endocannabinoid system in humans, which was only identified in the 1990s, is still a mystery in many ways. Although we know it helps to regulate physiological and cognitive processes and manufactured endocannabinoids that “act as neuromodulators,” just how this system can be tapped into with medication and drugs is a growing research avenue.

Cannabinoids are similar to endocannabinoids, which are manufactured by the human body to help in various processes, such as nerve function, energy metabolism, pain and inflammation and immune function, among others.

The report, published in BMJ Case Reports in October, describes how the woman’s tumour shrunk from 41 mm to 10 mm in roughly two and a half years.

While cannabinoids have been studied as a primary cancer treatment before, the results have been inconclusive and inconsistent, making it difficult to pinpoint if it actually had any impact.

During these scans over the next couple years, doctors observed that her lung cancer was shrinking. By February 2021, it had reduced by approximately 76 per cent in diameter, which averaged to a 2.4 per cent reduction per month since diagnosis.

“The supplier advised that the main active ingredients of the ‘CBD oil’ used by this patient were Δ9-tetrahydrocannabinol (THC) at 19.5 [per cent], CBD at 20.05 [per cent] and tetrahydrocannabinolic acid (THCA) at 23.8 [per cent],” the report stated.

The patient certainly believe the CBD oil made the difference, and was quoted in the report as being “over the moon” and intending to continue taking the CBD oil “indefinitely.”

“Although there appears to be a relationship between the intake of ‘CBD oil’ and the observed tumour regression, we are unable to conclusively confirm that the tumour regression is due to the patient taking ‘CBD oil’,” the report stated.

Doctors also acknowledged that they were unable to confirm the full list of ingredients in the CBD oil this particular patient took.

Cannabis and cannabinoids in general do have proven therapeutic uses, such as assisting with chronic pain, anxiety and sleep disorders, but research into whether cannabinoids could be used as a direct cancer treatment has not yet come up with a clear answer.

If the CBD oil did play a part in the woman’s tumour shrinking, doctors aren’t sure how the active ingredients worked together to achieve this. Previous research into CBD and THC as treatments for cancer have had contradictory results at times, with THC having been shown in some studies to decrease tumour growth, but has been shown to increase cancer cells in other studies.

When she was first diagnosed, even though she was a candidate for treatments aimed at curing her cancer, she declined surgery, radiotherapy and other treatments she was offered.

So doctors decided to simply perform regular CT scans to check up on the patient every three to six months.

But one case report does not prove the treatment works — yet.

In this case report, a woman in her 80s was diagnosed with “non-small cell” lung cancer in June 2018 after months of a suspicious cough. She was a life-long smoker, smoking roughly 68 packs a year, and had a background of “mild chronic obstructive pulmonary disease,” the report stated.

The report offered the patients’ perspective, in which she explained that she declined treatment because she had watched her late husband go through the struggle of radiotherapy.

“More research is needed to identify the actual mechanism of action, administration pathways, safe dosages, its effects on different types of cancer and any potential adverse side effects when using cannabinoids.”

Over the course of 2.5 years, the tumor continued to regress. By February 2021, it had shrunk to 10 mm, which represents an overall reduction of 76% in maximum axial diameter. The average rate of reduction was 2.4% per month throughout the monitoring period.

The patient declined conventional treatment. She underwent monitoring with regular CT scans every 3–6 months.

“We are aware of the limitations of this case report,” write the authors, led by Kah Ling Liew, MD, of Watford General Hospital, Watford, United Kingdom.

After 2.5 years, the CT scans showed that the tumor had shrunk to 10 mm.

After an initial CT scan, she underwent a CT-guided lung biopsy and was diagnosed with NSCLC (TNM stage T2bN0Mx). Further analysis of the tumor tissue showed that it was negative for ALK and EGFR mutations. PDL1 was expressed by <1% of the tumor cells. No distant metastases were detected.

Patient Declined Recommended Treatment.

The patient then disclosed that she had been ingesting CBD oil, which had been suggested to her by a family member. It was taken orally about two to three times a day.

The authors have disclosed no relevant financial relationships. Nutt chairs the scientific committee of the charity Drug Science, which receives unrestricted educational grants from some medical cannabis companies. Ernst and Freeman have disclosed no relevant financial relationships.

A subsequent CT scan revealed that the main tumor in her right middle lobe had shrunk from 41 mm to 33 mm. There were new bilateral upper lobe nodules, one in the left apex, which measured 4 mm, and one in right apex, which measured 6 mm.

“Although there appears to be a relationship between the intake of ‘CBD oil’ and the observed tumour regression, we are unable to conclusively confirm that the tumour regression is due to the patient taking ‘CBD oil,’ ” they comment.

The source of the CBD oil was outside the United Kingdom. The main active ingredients, according to her supplier, were Δ9-­tetrahydrocannabinol (THC), at 19.5%, CBD, at 20.05%, and tetrahydrocannabinolic acid, at 23.8%.

The patient was referred to cardiothoracic surgeons for a possible lobectomy, but the patient declined to have surgery. She was then referred to the oncologists. She underwent repeat CT and positron-emission tomography (PET) scans, which showed that her cancer had continued to shrink. On CT, there was an 11-mm reduction, and on PET, an 18-mm reduction. The left apical nodule had resolved, and the right upper lobe nodule was reduced in size.

Details of the case were published on October 14 in BMJ Case Reports.

A case report describes the dramatic shrinkage of a tumor to a quarter of its original size in a patient with non–small cell lung cancer (NSCLC) who had declined conventional treatment, continued smoking, and who later revealed that she was ingesting cannabidiol (CBD) oil.

The patient was contacted to discuss her results. She revealed that she was using CBD oil and that she had started taking it in August 2018. No changes had been made in her prescription medications, diet, and lifestyle, and she continued to smoke a pack of cigarettes every week.

“Case reports cannot be considered to be reliable evidence, and there are currently no data from rigorous clinical trials to suggest that cannabis products will alter the natural history of any cancer,” Ernst said.

The patient initially presented with a persistent cough that did not resolve with antibiotic therapy. She has a history of mild chronic obstructive pulmonary disease, osteoarthritis, and hypertension. She is a current smoker with a 68 pack-year history of smoking. She has no history of alcohol consumption and is taking several prescription medications.

Another expert, Edzard Ernst, MD, PhD, professor emeritus of complementary medicine, University of Exeter, Exeter, United Kingdom, pointed out that in animal models, cannabinoids have reduced the size of prostate cancer tumors. “Previous case reports have yielded encouraging findings also in human cancers,” he noted. He too said that further study is needed.

BMJ Case Rep. 2021;14:e244195. Full text.

At diagnosis, the tumor measured 41 mm, and there was no evidence of local or further spread. Hence, it was suitable for a standard treatment regimen of surgery, chemotherapy, and radiotherapy, note the authors.

He noted that a “case report itself is not sufficient to give any form of proof that one thing caused the other ― we need trials for that. There are some controlled trials already started and more are required to properly explore the potential of medical cannabis in a range of cancers.”

The patient was an 80-year-old woman.

Both points were emphasized by experts reacting to the publication via the UK Science Media Center.

“I was not very interested in traditional cancer treatments,” the patient said, “as I was worried about the risks of surgery, and I saw my late husband suffer through the side effects of radiotherapy. My relative suggested that I should try ‘cannabidiol (CBD) oil’ to treat my cancer, and I have been taking it regularly ever since. I am ‘over the moon’ with my cancer shrinking, which I believe was caused by the ‘CBD oil’. I am tolerating it very well and I intend to take this treatment indefinitely.”

The team also notes that there are similar case reports in the medical literature.

The patient was offered stereotactic ablative radiotherapy, but she declined this treatment. Because she had refused all standard therapies, a decision was made to “watch and wait.” The patient underwent regular CT surveillance.

“This case was brought to the attention of the local lung MDT [multidisciplinary team] in February 2019 when the serial imaging showed a reduction in tumor size despite having received no conventional treatment for her lung cancer,” write the authors.

“The product used by this patient reportedly contained high levels of THC (the intoxicating component of cannabis) and was sourced from outside the UK,” commented Tom Freeman, PhD, senior lecturer and director of the Addiction and Mental Health Group, University of Bath, Bath, United Kingdom. “This type of product is very different to most CBD oils, which predominantly contain CBD. Unlike prescribed medicines, CBD wellness products lack assurance of quality, safety, or efficacy and should not be used for medicinal purposes.”

“This is one of many such promising single case reports of medical cannabis self-treatment for various cancers,” said David Nutt, DM, FRCP, FRCPsych, the Edmond J. Safra Chair in Neuropsychopharmacology, Imperial College London, London, United Kingdom. “Such case reports are biologically credible given the adaptogenic nature of the endocannabinoid system.”

For more from Medscape Oncology, join us on Twitter and Facebook.